SunOpta Clears U.S. Antitrust Hurdle for Refresco Deal, Reducing Key Process Risk

What happened

SunOpta announced the early termination of the Hart-Scott-Rodino waiting period for its $6.50 per share cash acquisition by Refresco, removing a major U.S. regulatory overhang. This development directly addresses a critical swing factor identified in the DeepValue report, where an HSR second request could have delayed the deal beyond the targeted Q2 2026 close. The early termination signals no second request from U.S. authorities, lowering the probability of regulatory delays and supporting the base case scenario of a timely closure. However, significant hurdles remain, including the shareholder vote on April 16, 2026, and antitrust approvals in Canada and Vietnam, which are still pending and could disrupt the transaction. Despite this positive step, the stock price at $6.50 matches the offer, offering no upside to the deal consideration and leaving investors exposed to residual execution risks.

Implication

This news lowers the likelihood of a U.S. regulatory delay, which was a key bear case trigger with a 20% probability of deal failure. It reinforces the base scenario of a 70% chance for a Q2 2026 close, aligning with management's timeline and reducing process uncertainty. However, investors must still closely monitor the upcoming shareholder vote and international approvals, as any setbacks there could abruptly break the deal. At the current price of $6.50, which fully prices in the offer, the risk-reward remains poor due to limited spread compensation and asymmetric downside if the deal collapses. Therefore, while regulatory risk has diminished, the investment stance remains cautious, emphasizing the need for a discounted entry below $6.20 to justify exposure.

Thesis delta

The early HSR termination reduces the regulatory risk component, slightly increasing the odds of the base case outcome from 70% to potentially higher, though not quantified. However, the core thesis of a WAIT rating with an attractive entry at $6.20 remains unchanged, as the stock still trades at the full deal price with no margin of safety. This news does not alter the fundamental valuation or spread dynamics, leaving the investment call dependent on price dislocation rather than process improvements.